Liver toxicity associated with the use of pazopanib in renal cancer patients: UK teaching hospital experience.

• DOI: 10.1200/jco.2015.33.15_suppl.e15610
• Publication Date: 2019-03-07T22:22:25Z
• Authors: Ankit Jain; Cinzia Canipari; Farzana Haque; Heena Solanki; Abhishek Kumar; Emilio Porfiri
• Keywords: Pazopanib

e15610 Background: Hepatotoxicity has been observed in about 40-50% renal cancer patients treated with Pazopanib clinical trials. We have analysed the incidence of induced liver toxicity real world setting. Methods: A retrospective analysis was conducted on metastatic between December 2010 and September 2014, within two centres from Birmingham, UK. Data collected baseline demographics, overall survival. Results: total 89 were identified (59 male, 30 female). Median age 65 (range 17-91). 59 (66%) had prior nephrectomy. 75% PS 0-1 whereas 25% 2-3. metastases. duration treatment 25.14 weeks. 34 (38%) still 50 (56%) alive at time analysis. OS for all 17 months. 27 (30%) developed hepatotoxicity. 10 23 grades rise bilirubin ALT respectively 4 6 grade 3 or respectively. 20 continued 2 discontinued temporarily 5 permanently. hepatotoxicity 34.4 before 5.86 weeks 1.8 – 53.5). 7.71 (37%) treatment. 17.5 53/89 (59.5%) stopped Pazopanib- 36 (40.5%) disease progression, (11.2%) non-hepatic toxicity, (5.6%) hepatotoxicity, (2.2%) other reasons. Due to advanced age/ co-morbidities, 35 (39.3%) commenced a reduced dose (16 600mg, 19 400mg od). In these patients, did not differ those full dose. Conclusions: Our data shows lower rates as compared Reassuringly most cases mild settled without modifications. Frequency affected by age, presence